Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1598

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine Hydrochloride, showing its molecular configuration with aromatic rings and functional groups as part of the active ingredient's formula.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time between placebo and duloxetine delayed-release capsules. The x-axis represents time, while the y-axis shows the proportion of patients experiencing relapse. The graph features two lines: a dashed line for placebo and a solid line for duloxetine delayed-release capsules, indicating differences in relapse rates between the treatments.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier survival curve comparing relapse proportions over time between placebo and Duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph displays lower relapse rates for Duloxetine delayed-release capsules compared to placebo across the time period.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four groups are charted: DUL 60 mg BID, DUL 60 mg QD, DUL 20 mg QD, and placebo, showing patient response across varying improvement percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline among three groups: Duloxetine 60mg BID, Duloxetine 60mg QD, and placebo. The Y-axis shows the percentage of patients improved, and the X-axis shows percent improvement in pain. The graph illustrates trends in patient improvement across these treatments.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph comparing the percentage of patients improved relative to percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares data for Duloxetine Delayed-Release at dosages of 120 mg once daily, 60 mg once daily, 20 mg once daily, and a placebo group. The graph depicts decreasing percentages of patients improved as pain improvement percentage increases.*

FDA Label Image

Figure 7 (Duloxetine 08)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. Two lines represent comparison groups: Duloxetine 60 mg once daily and placebo. The graph illustrates higher patient improvement rates over increasing pain relief percentages for Duloxetine compared to placebo, including annotations regarding dosage and patient assessment methods.*

FDA Label Image

Figure 8 (Duloxetine 09)

A percentage improvement in pain chart comparing Duloxetine Delayed-Release 60/120 mg once daily with placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The chart illustrates that a higher percentage of patients improved with Duloxetine compared to placebo across various improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 10)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline (BOCF) for two groups: placebo and Duloxetine 60 mg once daily (DUL). The graph shows a trend of higher improvement percentages for Duloxetine across increasing pain improvement thresholds.*

FDA Label Image

Figure 10 (Duloxetine 11)

A line graph comparing the percent improvement in pain from baseline (BOCF) between placebo and Duloxetine delayed-release (60/120 mg once daily) groups. The x-axis represents percent improvement in pain, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. The graph displays higher patient improvement percentages in the Duloxetine group than the placebo across most levels of pain improvement.*

FDA Label Image

Label (Lbl721621598)

Label for Duloxetine Delayed-Release Capsules, USP, 30 mg strength. The label shows the NDC number 72162-1598 for a package containing 90 capsules. The product contains 33.7 mg of Duloxetine Hydrochloride equivalent to 30 mg Duloxetine. It is labeled by Bryant Ranch Prepack and manufactured by Towa Pharmaceutical Europe.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.